SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells

Abstract

SOX11 is an embryonic mammary epithelial marker that is normally silenced prior to birth. High SOX11 levels in breast tumours are significantly associated with distant metastasis and poor outcome in breast cancer patients. Here, we show that SOX11 confers distinct features to ER-negative DCIS.com breast cancer cells, leading to populations enriched with highly plastic hybrid epithelial/mesenchymal cells, which display invasive features and alterations in metastatic tropism when xenografted into mice. We found that SOX11+DCIS tumour cells metastasize to brain and bone at greater frequency and to lungs at lower frequency compared to cells with lower SOX11 levels. High levels of SOX11 leads to the expression of markers associated with mesenchymal state and embryonic cellular phenotypes. Our results suggest that SOX11 may be a potential biomarker for breast tumours with elevated risk of developing metastases and may require more aggressive therapies.

Data availability

Sequencing data have been deposited in ArrayExpress as accession E-MTAB-9108. All data generated or analysed during this study are included in the manuscript and supporting files.

The following data sets were generated

Article and author information

Author details

  1. Erik Oliemuller

    The Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4506-0504
  2. Richard Newman

    The Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Siu Man Tsang

    The Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Shane Foo

    Translational Immunotherapy Team, Division of Radiotherapy and Imaging,, The Institute of Cancer Research, London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Gareth Muirhead

    The Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Farzana Noor

    The Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Syed Haider

    The Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Iskander Aurrekoetxea-Rodríguez

    Basque Research and Technology Alliance (BRTA), CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  9. Maria dM Vivanco

    Cell Biology and Stem Cells Unit, CIC bioGUNE, Derio, Spain
    Competing interests
    The authors declare that no competing interests exist.
  10. Beatrice A Howard

    The Breast Cancer Now Toby Robins Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, London, United Kingdom
    For correspondence
    beatrice.howard@icr.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9162-0314

Funding

Breast Cancer Now (Programme Funding to the Breast Cancer Now Toby Robins Research Centre)

  • Erik Oliemuller
  • Richard Newman
  • Siu Man Tsang
  • Gareth Muirhead
  • Farzana Noor
  • Syed Haider
  • Beatrice A Howard

Cancer Research UK (CRUK: A21855)

  • Shane Foo

Spanish Ministry of Education and Science (SAF2017-84934-R)

  • Maria dM Vivanco

Government of the Autonomous Community of the Basque Country, the Department of Industry, Tourism and Trade

  • Iskander Aurrekoetxea-Rodríguez
  • Maria dM Vivanco

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Kay F Macleod, University of Chicago, United States

Ethics

Animal experimentation: All animal work was carried out under UK Home Office PPL number: PB0FA698C (BAH Project licence holder) and personal licenses following local ethical approval of all protocols from The Institute of Cancer Research Ethics Committee and in accordance with local and national guidelines. All surgery was performed under isoflurane anesthesia with appropriate analgesia, and every effort was made to minimise suffering.

Version history

  1. Received: April 28, 2020
  2. Accepted: September 9, 2020
  3. Accepted Manuscript published: September 10, 2020 (version 1)
  4. Version of Record published: September 25, 2020 (version 2)

Copyright

© 2020, Oliemuller et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,097
    views
  • 279
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Erik Oliemuller
  2. Richard Newman
  3. Siu Man Tsang
  4. Shane Foo
  5. Gareth Muirhead
  6. Farzana Noor
  7. Syed Haider
  8. Iskander Aurrekoetxea-Rodríguez
  9. Maria dM Vivanco
  10. Beatrice A Howard
(2020)
SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells
eLife 9:e58374.
https://doi.org/10.7554/eLife.58374

Share this article

https://doi.org/10.7554/eLife.58374

Further reading

    1. Cancer Biology
    2. Cell Biology
    Julian J A Hoving, Elizabeth Harford-Wright ... Alison C Lloyd
    Research Article

    Collective cell migration is fundamental for the development of organisms and in the adult, for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell-cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell-cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during rat Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell-cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell-surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective Schwann cell migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased Schwann cell collective migration and increased clustering of Schwann cells within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.

    1. Cancer Biology
    2. Structural Biology and Molecular Biophysics
    Johannes Paladini, Annalena Maier ... Stephan Grzesiek
    Research Article

    Abelson tyrosine kinase (Abl) is regulated by the arrangement of its regulatory core, consisting sequentially of the SH3, SH2, and kinase (KD) domains, where an assembled or disassembled core corresponds to low or high kinase activity, respectively. It was recently established that binding of type II ATP site inhibitors, such as imatinib, generates a force from the KD N-lobe onto the SH3 domain and in consequence disassembles the core. Here, we demonstrate that the C-terminal αI-helix exerts an additional force toward the SH2 domain, which correlates both with kinase activity and type II inhibitor-induced disassembly. The αI-helix mutation E528K, which is responsible for the ABL1 malformation syndrome, strongly activates Abl by breaking a salt bridge with the KD C-lobe and thereby increasing the force onto the SH2 domain. In contrast, the allosteric inhibitor asciminib strongly reduces Abl’s activity by fixating the αI-helix and reducing the force onto the SH2 domain. These observations are explained by a simple mechanical model of Abl activation involving forces from the KD N-lobe and the αI-helix onto the KD/SH2SH3 interface.